Organon has announced a major commercial agreement with Daiichi Sankyo Europe to bring Nilemdo (bempedoic acid) to France, Denmark, Iceland, Sweden, Finland, and Norway. The first-in-class drug targets patients with high cholesterol and cardiovascular disease risk, providing a vital alternative for those who cannot tolerate statins.

 

“This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” said Thibault Crosnier Leconte, AVP & Managing Director at Organon Northwest Europe. 

 

“By offering a new treatment option for patients who cannot tolerate statins, we are helping to close a persistent gap in cardiovascular care—one that disproportionately affects women – whilst reinforcing our mission to deliver impactful treatments for a healthier every day.”

 

Cardiovascular disease remains the leading cause of death in Europe and worldwide for women, yet it continues to be under-recognized, under-diagnosed, and under-treated. Nilemdo is the first and only therapy in its class available in these markets, giving healthcare professionals a new tool to lower cardiovascular risk in patients unable to achieve adequate LDL-C reduction through statins or other lipid-lowering therapies.

 

Under the agreement, Organon will handle the distribution and promotion of Nilemdo in the six countries, while Daiichi Sankyo Europe retains marketing authorization. Organon will act as the local representative for the product in the region.